PANews reported on October 7 that according to Globenewswire, MAIA Biotechnology, listed on NYSE American under the New York Stock Exchange, announced the official launch of its crypto treasury strategy. At the same time, its board of directors has approved investing 90% of the company's liquid assets in leading cryptocurrencies. The initial investment will purchase BTC, ETH and USDC. It is reported that the company will also establish a digital asset advisory committee to provide support for related purchase transactions.